← Leaderboards
Theresa A Guise
University Of Texas Hlth Sci Ctr San Ant
$8,674,181
Attributed
$12,159,036
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$12,159,036 · 8
By mechanism
R01$8,908,547 · 4
U01$2,654,798 · 1
P01$494,191 · 2
R29$101,500 · 1
Top collaborators
- Andrew R Marks9 shared
- Paul Richard Territo9 shared
- Neil A Bhowmick5 shared
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- G David Roodman$13,528,230
- Gregory R Mundy$7,763,862
- Hanna E Abboud$7,966,394
Others in their field
Top investigators on “Metastatic Neoplasm To The Bone”
- David Heimbrook · Leidos Biomedical Research, Inc.$29,594,272
- Electra D. Paskett · Ohio State University$25,776,971
- Olwen Hahn · Brigham And Women'S Hospital$13,576,315
- Deborah W Bruner · American College Of Radiology$12,985,448
- Evan Todd Keller · University Of Michigan At Ann Arbor$12,961,716
- Joan Massague · Sloan-Kettering Institute For Cancer Res$11,778,928
Research focus
Metastatic Neoplasm To The BoneIn VivoBone NeoplasmsOsteoblastsResponseSignal TransductionTumorMouse ModelNeoplasm MetastasisResearch PersonnelSamplingPreventCell LineGrowth FactorIn VitroAnimal ModelNeoplastic CellBone ResorptionBehaviorAthymic MouseBreastMalignant Neoplasm Of ProstateOsteoclastsPhenotype
Grant awards (48)
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$600,621
R01 · FY2020 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$604,910
R01 · FY2019 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$20,000
R01 · FY2019 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$15,365
R01 · FY2019 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$630,724
R01 · FY2018 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$52,355
R01 · FY2018 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$20,000
R01 · FY2018 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$637,172
R01 · FY2017 · CA · contact PI
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.$655,037
R01 · FY2016 · CA · contact PI
Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth$537,942
U01 · FY2015 · CA · contact PI
Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth$521,804
U01 · FY2014 · CA · contact PI
Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth$505,665
U01 · FY2013 · CA · contact PI
Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth$537,945
U01 · FY2012 · CA · contact PI
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS$272,224
R01 · FY2012 · CA · contact PI
Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth$551,442
U01 · FY2011 · CA · contact PI
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS$272,224
R01 · FY2011 · CA · contact PI
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS$280,643
R01 · FY2010 · CA · contact PI
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS$276,088
R01 · FY2009 · CA · contact PI
Cell, Animal and Imaging Core$190,379
P01 · FY2009 · CA · contact PI
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN$179,513
R01 · FY2009 · DK · contact PI
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN$155,245
R01 · FY2009 · DK · contact PI
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN$333,010
R01 · FY2008 · DK · contact PI
TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS$276,088
R01 · FY2008 · CA · contact PI
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING$233,262
R01 · FY2008 · DK · contact PI
Cell, Animal and Imaging Core$122,298
P01 · FY2008 · CA · contact PI
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING$52,420
R01 · FY2008 · DK · contact PI
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN$339,805
R01 · FY2007 · DK · contact PI
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING$289,195
R01 · FY2007 · DK · contact PI
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$128,298
R01 · FY2007 · CA · contact PI
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN$349,954
R01 · FY2006 · DK · contact PI
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING$297,833
R01 · FY2006 · DK · contact PI
PROSTATE CANCER BONE METASTASES: ROLE OF ADRENOMEDULLIN$358,081
R01 · FY2005 · DK
ENDOTHELIN-1 IN NORMAL AND PATHOLOGICAL BONE REMODELING$304,667
R01 · FY2005 · DK
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$261,853
R01 · FY2005 · CA
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$261,383
R01 · FY2004 · CA
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$260,924
R01 · FY2003 · CA
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$178,028
R01 · FY2002 · CA
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$71,570
R01 · FY2002 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$0
P01 · FY2002 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$0
P01 · FY2002 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$0
P01 · FY2002 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$0
P01 · FY2002 · CA
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$232,830
R01 · FY2001 · CA
Breast Cancer Osteolysis--Regulation of PTHrP by TGFBeta$7,225
R01 · FY2001 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$0
P01 · FY2001 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$0
P01 · FY2001 · CA
Molecular mechanisms of osteoblastic bone metastasis: Role of endothelin-1$181,514
P01 · FY2000 · CA
BREAST CANCER METASTASES TO BONE--ROLE OF PTHRP &TGFB$101,500
R29 · FY2000 · CA